BERLIN 2025 ESMO congress

LBA102

Efficacy and safety of ponsegromab in patients with cancer-associated cachexia: Results from the open-label extension of a randomized, placebo-controlled, phase II study

J. Crawford[1], J. Groarke[2], S. Collins[3], S. Lubaczewski[4], E.J. Roeland[5], T. Naito[6], A. Hendifar[7], M.T. Fallon[8], K. Takayama[9], T.R. Asmis[10], R. Dunne[11], M. Rossulek[12], R. Qiu[2], A. Saxena[2]

[1] Duke Cancer Institute, Duke Cancer Institute, Durham, United States of America, [2] Medical Oncology, Pfizer Inc., Groton, United States of America, [3] Medical Oncology, Pfizer Inc, San Diego, United States of America, [4] Medical Oncology, Pfizer Inc - USA, New London, United States of America, [5] Knight Cancer Institute, Oregon Health and Science University, Portland, United States of America, [6] Medical Oncology, Shizuoka Cancer Center, Shizuoka, Japan, [7] Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, United States of America, [8] Palliative Medicine, Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom, [9] Medical Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, [10] Medical Oncology Department, The Ottawa Hospital Regional Cancer Centre, Ottawa, Canada, [11] Medical Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, United States of America[12] Medical Oncology, Pfizer Inc, San Diego, United States of America

Background

Ponsegromab, a first-in-class monoclonal antibody that inhibits growth differentiation factor 15 (GDF-15), improved body weight, symptoms, physical activity, and muscle mass in patients with cancer cachexia in a 12-week, double blind phase 2 trial (Part A; NCT05546476). We report the findings of the 1-year, open-label extension (Part B).

Methods

Participants with cancer cachexia and elevated serum GDF-15 (≥1500 pg/mL) received subcutaneous (SC) ponsegromab (100, 200, or 400 mg) or matching placebo every 4 weeks (Q4W) during Part A. At 12 weeks, participants could pursue open-label treatment with ponsegromab 400 mg Q4W SC through week 64 (Part B). Change in body weight and safety were assessed through weeks 64 and 72, respectively.

Results

Of 137 participants who completed Part A, 117 (85.4%) participants (44.4% non-small cell lung, 29.1% colorectal, and 26.5% pancreatic cancer; 70.9% stage 4) opted into Part B. Median (IQR) age and weight at baseline were 68 (61,74) years and 54.7 (46.0, 63.8) kg, respectively. Overall, progressive weight gains were observed with mean (SD) increases of 2.74 (4.89) kg, 4.43 (5.95) kg, and 5.18 (5.93) kg at weeks 24, 52, and 64, respectively. Weight gains were lowest in participants assigned to placebo in Part A (Table). All-causality and treatment-related adverse events were reported in 84.2% and 4.4% of participants from weeks 12-72, respectively. Of the 23 deaths during Part B, 19 (82.6%) were reported as due to malignancy and none were treatment-related.Table: LBA102

	Baseline		Wk 12		Wk 24		Wk 52		Wk 64	
	N	Mean (SD) weight, kg	N	Mean (SD) CFB, kg	N	Mean (SD) CFB, kg	N	Mean (SD) CFB, kg	N	Mean (SD) CFB, kg
All Part B Participants	117	56.2 (12.3)	114	+1.26 (3.68)	81	+2.74 (4.89)	43	+4.43 (5.95)	37	+5.18 (5.93)
PART A → PART B TREATMENT										
Placebo → Pons 400 mg	26	53.4 (10.7)	24	-0.30 (2.03)	18	+0.89 (2.49)	6	+1.63 (3.90)	6	+2.28 (3.41)
Pons 100 mg →Pons 400 mg	27	52.8 (12.8)	27	+0.84 (3.18)	21	+1.68 (4.51)	11	+4.86 (4.58)	9	+5.57 (4.48)
Pons 200 mg →Pons 400 mg	35	58.5 (13.8)	34	+1.36 (3.70)	23	+4.01 (4.70)	14	+4.67 (7.43)	11	+4.01 (6.78)
Pons 400 mg →Pons 400 mg	29	58.9 (10.4)	29	+2.83 (4.57)	19	+4.11 (6.47)	12	+5.15 (6.22)	11	+7.61 (6.72)

Abbreviations: CFB- change from baseline; Pons- ponsegromab.

Conclusions

Improvements in body weight during 12-week Part A were maintained with ponsegromab through 64 weeks in Part B. Participants assigned to placebo in Part A showed stabilization of weight during Part B, but weight gain was less than for participants who received ponsegromab during Part A. Ponsegromab continued to be safe and well-tolerated through 72 weeks with no new safety signals.

Clinical trial identification

NCT05546476.

Legal entity responsible for the study

The study is sponsored by Pfizer.

Funding

The study is funded by Pfizer.

Disclosure

J. Crawford: Financial Interests, Personal, Advisory Board: Actimed, Gen Sci, Tensegrity; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board, DSMB: BioAtla, G1 Therapeutics; Financial Interests, Institutional, Local PI: AstraZeneca; Financial Interests, Personal, Steering Committee Member: Pfizer. J. Groarke: Financial Interests, Institutional, Full or part-time Employment: Pfizer; Financial Interests, Institutional, Stocks/Shares: Pfizer. S. Collins: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. S. Lubaczewski: Financial Interests, Institutional, Full or part-time Employment: Pfizer; Financial Interests, Institutional, Stocks/Shares: Pfizer. E.J. Roeland: Financial Interests, Personal, Advisory Board: Napo Pharmaceuticals; Financial Interests, Personal, Advisory Board, Expert Witness: Heron Therapeutics; Financial Interests, Institutional, Local PI: Pfizer; Non-Financial Interests, Member, Evidence-based Guidelines committee: American Society of Clinical Oncology. T. Naito: Financial Interests, Personal, Advisory Board: Pfizer Inc., Tensegrity Pharma, Inc., AstraZeneca K.K., Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Invited Speaker: ONO Pharmaceutical CO. Ltd, Tsumura & Co.; Financial Interests, Institutional, Research Grant: Otsuka Pharmaceutical CO. Ltd., Kracie, Ltd.. A. Hendifar: Financial Interests, Personal, Advisory Board: Ipsen, exelexis; Financial Interests, Institutional, Local PI: Merck, Pfizer, Faeth, cantex, inspirna, elicio; Financial Interests, Personal, Other, I am on the DSMC: rayzebio; Non-Financial Interests, Other, Steering Committee: Pfizer (Any division); Non-Financial Interests, Advisory Role, SMAB: PANCAN. M.T. Fallon: Financial Interests, Institutional, Advisory Board, Steering Committee as outlined: Pfizer; Financial Interests, Institutional, Coordinating PI, Support for PhD student for MINT study: Mentholatum; Financial Interests, Institutional, Local PI, Pfizer funded research study, completed 2022: Pfizer; Financial Interests, Institutional, Other, Provision of IMP/MRX1 for NIHR funded CBD study: MRX Ananda; Financial Interests, Institutional, Steering Committee Member, Steering committee member for phase 2 and phase 3 Ponsegromab studies: Pfizer. K. Takayama: Financial Interests, Personal, Member of Board of Directors: Japan Lung Cancer Society; Financial Interests, Personal, Member: West Japan Onc Group. T.R. Asmis: Financial Interests, Personal, Advisory Board: Pfizer, Merck, AstraZeneca, Bristol Myers Squibb International, Novartis, Eisai. R. Dunne: Financial Interests, Personal, Advisory Board: Exelixis, Incyte, Merck; Non-Financial Interests, Advisory Role: Pfizer. M. Rossulek: Financial Interests, Institutional, Full or part-time Employment: Pfizer; Financial Interests, Institutional, Stocks/Shares: Pfizer. R. Qiu: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. A. Saxena: Financial Interests, Institutional, Full or part-time Employment: Pfizer; Financial Interests, Institutional, Stocks/Shares: Pfizer.